BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10
Cellular Signalling · 2024
DOI: 10.1016/j.cellsig.2024.111173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2024. Verfasst von Yongyi Ma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathogenic Biology, School of Medicine, Nantong University, Nantong 226001, China; Laboratory of Medical Science, School of Medicine, N…. Hauptthemen laut MEDLINE: Transcription Factors, Proto-Oncogene Proteins c-myc, Cell Cycle Proteins, S100 Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Nantong Municipality, Natural Science Research of Jiangsu Higher Education Institutions of China.
Abstract (Originalsprache)
Targeted therapy based on BRD4 and MYC shows promise due to their well-researched oncogenic functions in cancer, but their tumor-suppressive roles are less understood. In this study, we employ a systematic approach to delete exons that encode the low-complexity domain (LCD) of BRD4L in cells by using CRISPR-Cas9. In particular, the deletion of exon 14 (BRD4-E14) results in cellular morphological changes towards spindle-shaped and loosely packed. BRD4-E14 deficient cells show increased cell migration and reduced cell adhesion. The expression of S100A10 was significantly increased in cells lacking E14. BRD4L binds with MYC via the E14-encoded region of the LCD to inhibit the expression of S100A10. In cancer tissues, there is a positive correlation between BRD4 and MYC, while both of these proteins are negatively associated with S100A10 expression. Finally, knocking out the BRD4-E14 region or MYC promotes tumor growth in vivo. Together, these data support a tumor-suppressive role of BRD4L and MYC in some contexts. This discovery emphasizes the significance of a discreetly design and precise patient recruitment in clinical trials that testing cancer therapy based BRD4 and MYC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathogenic Biology, School of Medicine, Nantong University, Nantong 226001, China; Laboratory of Medical Science, School of Medicine, Nantong University, Nantong 226001, China.
- Laboratory of Medical Science, School of Medicine, Nantong University, Nantong 226001, China; Department of Gastroenterology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 2260…
- Department of Pathophysiology, School of Medicine, Nantong University, Nantong 226001, China.
- Department of Pathogenic Biology, School of Medicine, Nantong University, Nantong 226001, China.
- Department of Stomatology, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong 226001, China.
- Laboratory of Medical Science, School of Medicine, Nantong University, Nantong 226001, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Nantong Municipality
- Natural Science Research of Jiangsu Higher Education Institutions of China
- Nantong University
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Ma, Y., Liu, N., Shi, Y., Ma, S., Wang, Y., Zheng, W., Sun, R., Song, Y., Chen, M., Qu, L., Mao, R., & Fan, Y. (2024). BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2024.111173
Vancouver
Ma Y, Liu N, Shi Y, Ma S, Wang Y, Zheng W, et al. BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10. Cellular Signalling. 2024. doi:10.1016/j.cellsig.2024.111173
BibTeX
@article{Ma2024,
author = {Ma, Yongyi and Liu, Nan and Shi, Yu and Ma, Shuyan and Wang, Yingjun and Zheng, Wen and Sun, Rong and Song, Yihua and Chen, Miaomiao and Qu, Lishuai and Mao, Renfang and Fan, Yihui},
title = {BRD4L cooperates with MYC to block local tumor invasion via suppression of S100A10},
journal = {Cellular Signalling},
year = {2024},
doi = {10.1016/j.cellsig.2024.111173}
}
EUVIMED